A single-arm phase II study of alemtuzumab in combination with high-dose methylprednisolone in CLL [chronic lymphocytic leukaemia] patients with p53 deletion.

Trial Profile

A single-arm phase II study of alemtuzumab in combination with high-dose methylprednisolone in CLL [chronic lymphocytic leukaemia] patients with p53 deletion.

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2016

At a glance

  • Drugs Alemtuzumab (Primary) ; Alemtuzumab (Primary) ; Methylprednisolone
  • Indications Chronic lymphocytic leukaemia
  • Focus Therapeutic Use
  • Acronyms CAM-PRED
  • Most Recent Events

    • 31 May 2012 Additional lead trial centre identified as reported by UKCRN.
    • 09 Apr 2012 Final results have been published in the Journal of Clinical Oncology.
    • 20 Aug 2010 New source identified and integrated (ISRCTN: Current Controlled Trials).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top